ABGX, GLIA antibody deal

Abgenix (ABGX) received exclusive worldwide development and marketing rights to human monoclonal antibodies against complement protein properdin from Gliatech (GLIA) for all indications, including cardiovascular and inflammatory diseases. Under a 2000 deal, ABGX used its XenoMouse technology to produce the anti-properdin antibodies, and GLIA had rights to resulting products. GLIA President Steven Basta told BioCentury that "we're not an antibody development company. We therefore wanted a partner for the properdin antibodies with multiple antibodies and clinical trial experience." ...